Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MiMedx Group ( (MDXG) ) has provided an announcement.
On June 18, 2025, MiMedx Group held its Annual Meeting of Shareholders, where 85.7% of the voting shares were represented. During the meeting, nine directors were re-elected, an advisory resolution on executive compensation was approved, Deloitte & Touche LLP was ratified as the independent auditor for 2025, an amendment to the 2016 Equity and Cash Incentive Plan was approved, and it was decided that the advisory vote on executive compensation would occur annually.
The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.
Spark’s Take on MDXG Stock
According to Spark, TipRanks’ AI Analyst, MDXG is a Outperform.
MiMedx Group’s strong financial performance and strategic growth initiatives are key strengths, supported by robust cash flow and positive earnings call highlights. However, bearish technical indicators and valuation concerns slightly temper the overall outlook.
To see Spark’s full report on MDXG stock, click here.
More about MiMedx Group
Average Trading Volume: 659,554
Technical Sentiment Signal: Sell
Current Market Cap: $871.4M
For a thorough assessment of MDXG stock, go to TipRanks’ Stock Analysis page.